Sandra O'Sullivan

In this Parexel study, David Barratt, SVP, Enterprise Account Leader, highlights the case for tokenization in linking RWD with patient insights. Explore how Parexel utilizes innovative data science techniques to gather insights into patient experiences, treatment preferences, and social determinants of health. This approach provides a comprehensive view of the patient journey, enabling more informed and patient-centric clinical decisions while protecting sensitive data. Read the full report from our study here: https://lnkd.in/gmrUrxMN #ParexelBiotech #Tokenization #RWD #PatientInsights

29

Looking to empower your oncology trials with specialized CRO training? Our latest white paper dives into the critical role CRAs play in managing advanced oncology trials and how specialized training can help set up your trial for success. Download your copy today! https://bit.ly/48k1RHG

4

🤔 Would you take a pay cut or demotion to keep your job? A recent BioSpace article from a best in class journalists Angela Gabriel reveals some intriguing insights: 📊 33% of biopharma professionals would take a pay cut to avoid layoffs 📉 22% would accept a demotion 🤯 43% of surveyed biotech and pharma professionals are currently unemployed The article dives deep into the pros and cons of these tough choices, featuring real stories from industry professionals who've faced these dilemmas. Key takeaways: • Your career stage matters in decision-making • Negotiated exits can be a viable alternative • Layoffs can be opportunities for reinvention As our industry faces ongoing challenges, it's crucial to consider our options carefully. What would you do in this situation? Share your thoughts below! 👇 #BiopharmaJobs #CareerChoices #ProfessionalDevelopment #LayoffStrategies

2

1 Comment

When conducting a clinical trial, you must ensure that you maximize your chances of success. Identifying the best sites and recruiting the right participants are two of the most crucial steps - failing at this stage means your trial won't even get off the ground. Join WCG for our upcoming webinar where we discuss how these aspects of a clinical trial must continually evolve, and learn best practices of how to set yourself, and your trial, up for success!

14

In this interview with Triangle Business Journal, CEO Peyton Howell shares her vision for how Parexel will tackle global challenges and leverage cutting-edge technology to reach more patients where they are. Read it: https://lnkd.in/gqS-FRmJ #PatientsFirst

39

1 Comment

There are many things to consider when running a clinical trial with an AAV gene therapy and seroprevalence of neutralizing antibodies against AAV is one of them. Read the article by my colleague Christos J Petropoulos and team to learn more about the prevalence of neutralizing antibodies across different demographics. #genetherapy #AAVgenetherapy #NAb

8

🌟 A much-anticipated win for Gilead Sciences with the approval of seladelpar for PBC, an asset they gained from the CymaBay Therapeutics acquisition. Strategic and Competitive Implications: 📣Branded as #Livdelzi, intends to increase market presence/share in inflammatory/GI/liver disease treatments beyond their strong, traditional focus in HIV, Oncology, and hepatitis. ⚕ Unique MOA, may be used alone or in combination with other treatments 📈 Market potential: Approximately 1/3 of PBC patients don't respond to first-line treatment. This newly approved option may drive revenue growth for Gilead. #GI #Liver #PrimaryBiliaryColangitis #RegulatoryAffairs #Pharma #Biotech #Innovation #Healthcare

4

1 Comment